Search our blog for articles and insights right here, just type your interest and dive into a world of knowledge.
Popular articles
FDA Approves Second Alzheimer's Drug
The U.S. Food and Drug Administration has granted approval to Eli Lilly's donanemab, now known as Kisunla, for the treatment of patients in the early stages of Alzheimer's disease. This marks the second drug to receive such approval, aimed at decelerating the progression of this debilitating brain-wasting condition.
The FDA's decision reflects the unanimous backing of an external panel of experts, who recommended Kisunla's use for early Alzheimer's patients after determining that the drug's benefits surpass its associated risks. Eli Lilly has set the cost of Kisunla at $695.65 per vial, translating to $32,000 for a full year’s treatment.
